Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)

Official Title

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Summary:

This study will evaluate the safety and efficacy of MK-4280 in combination with pembrolizumab (MK-3475) in participants with hematological malignancies: - classical Hodgkin lymphoma (cHL) - diffuse large B-cell lymphoma (DLBCL) - indolent non-Hodgkin lymphoma (iNHL) The study will have 2 phases: a safety lead-in and an efficacy expansion phase. The recommended Phase 2 dose (RPTD) will be determined in the safety lead-in phase by evaluating dose-limiting toxicities.

Trial Description

Primary Outcome:

• Percentage of Participants Experiencing a Dose-limiting Toxicity (DLT)
• Percentage of Participants Experiencing an Adverse Event (AE)
• Percentage of Participants with Treatment Discontinuations Due to an AE

• Objective Response Rate (ORR)
• Serum Concentration of MK-4280
• Serum Concentration of Pembrolizumab

View this trial on ClinicalTrials.gov